NCT05515796 is a Phase 2 clinical trial of Terelizumab (aka Tislelizumab) in Immunotherapy, sponsored by Daping Hospital and the Research Institute of Surgery of the Third Military Medical University.

What drugs are being tested in NCT05515796?

Interventions in NCT05515796: Terelizumab (aka Tislelizumab), CapeOx, Trastuzumab, Radiotherapy.

What condition does NCT05515796 study?

NCT05515796 studies Immunotherapy, Gastric Cancer, Rectal Cancer, Chemotherapy Effect, Radiotherapy.

Is NCT05515796 still recruiting?

NCT05515796 is currently completed. Last updated 1 April 2026.

Last reviewed 2026-04-01 · How we verify

NCT05515796

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors

Completed Phase 2 Last updated 1 April 2026

What this trial tests

Phase 2 trial testing Terelizumab (aka Tislelizumab) in Immunotherapy in 189 participants. Completed in 25 March 2026.

Timeline

1 September 2022

Primary endpoint
25 March 2026

25 March 2026

Quick facts

Lead sponsor	Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	189
Start date	1 September 2022
Primary completion	25 March 2026
Estimated completion	25 March 2026
Sites	1 location across China

Drugs / interventions tested

Terelizumab (aka Tislelizumab) — full drug profile →
CapeOx — full drug profile →
Trastuzumab (trastuzumab) — full drug profile →
Radiotherapy — full drug profile →

Conditions studied

Immunotherapy — all drugs for Immunotherapy →
Gastric Cancer — all drugs for Gastric Cancer →
Rectal Cancer — all drugs for Rectal Cancer →
Chemotherapy Effect — all drugs for Chemotherapy Effect →

Sponsor

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

Who can join

19 and older, any sex, with Immunotherapy or Gastric Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

immunotherapy，gastric cancer，rectal cancer，biomark

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Translational Bioinformatics Applied to the Study of Complex Diseases.
Casotti MC, Meira DD, Alves LNR, Bessa BGO, et al · · 2023 · cited 12× · PMID 36833346 · DOI 10.3390/genes14020419
Intestinal Subtype as a Biomarker of Response to Neoadjuvant Immunochemotherapy in Locally Advanced Gastric Adenocarcinoma: Insights from a Prospective Phase II Trial.
Wang L, Sun M, Li J, Wan L, et al · · 2025 · cited 7× · PMID 39495175 · DOI 10.1158/1078-0432.ccr-24-2436
Reduced intestinal-to-diffuse conversion and immunosuppressive responses underlie superiority of neoadjuvant immunochemotherapy in gastric adenocarcinoma.
Wang L, Wan L, Chen X, Gao P, et al · · 2024 · cited 3× · PMID 39473903 · DOI 10.1002/mco2.762
Spatial determinants of response to neoadjuvant radiotherapy and immunochemotherapy in locally advanced mismatch repair proficient rectal cancer
Li F, Shen H, He z, Chen Y, et al · · 2024 · DOI 10.21203/rs.3.rs-4657778/v1

Verify or expand the search:

Other recruiting trials for Immunotherapy

Currently open trials in the same condition.

NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
NCT07475403 — Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer · Phase 2 · recruiting
NCT07458529 — Neoadjuvant Chemoradiotherapy Plus Tislelizumab With or Without Probio-M9 in pMMR/MSS Locally Advanced Rectal Cancer · Phase 2 · recruiting
NCT07436845 — Impact of Emotional Status on Prognosis of Patients With BCLC Stage B/C Hepatocellular Carcinoma Undergoing Hepatic Arte · recruiting
NCT06671613 — Evaluating a Fasting-mimicking Diet in Combination With Immunotherapy in Patients With Non-small Cell Lung Cancer · NA · recruiting

Other Daping Hospital and the Research Institute of Surgery of the Third Military Medical University trials

Trials by the same sponsor.

NCT07468630 — Tolecizumab Plus Chemoimmunotherapy for pMMR/MSS Locally Advanced Colon Adenocarcinoma · Phase 2 · recruiting
NCT07459192 — Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors · not yet recruiting
NCT07459179 — Clinical Study on the Application of PET Probes Targeting DDR2 in the Diagnosis of Interstitial Lung Disease With Cognit · not yet recruiting
NCT07467590 — Combination of High and Low-Dose Radiotherapy With Immune Therapy and TKI in Advanced Colorectal Cancer: A Phase II Stud · Phase 2 · not yet recruiting
NCT07459205 — Clinical Application of 68Ga-1A12 PET in Fibrosis-related Diseases · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05515796 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Last refreshed: 1 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05515796.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing